[PDF] Top 20 Capacidad jurídica de las personas con discapacidad en el código civil y comercial

... a small Phase II trial of nimotuzumab with irinotecan in refractory CRC, there was a difference in overall survival between patients whose tumors were K-ras wild type compared with those with K-ras mutant ... See full document

... in non-small cell lung cancer, and several therapeutic agents that target this receptor, including EGFR tyrosine kinase inhibitors and monoclonal antibodies to EGFR, have been ... See full document

... ized to receive gefitinib 250 mg/day until progression or unacceptable toxicity or BSC. Primary endpoint was PFS. The results showed no statistical difference in outcome for patients treated with gefitinib, even though ... See full document

... Abstract: Lung cancer (LC) is one of the most important malignant and devastating tumors, the leading cause of cancer-related deaths ...of lung cancer is non-small ... See full document

... the treatment of patients with advanced non-small-cell lung can- cer (NSCLC) based on Phase II clinical trials since ...EGFR-TKI treatment, and gefitinib, which is not effective ... See full document

... 270 advanced TKI-naïve, ALK-positive NSCLC patients with no more than one prior line of systemic treatment will be randomized (1:1) to receive brigatinib (1 week at 90 mg daily followed by 180 mg daily) or ... See full document

... The treatment options for metastatic non-small-cell lung cancer (NSCLC) have expanded dramatically in the last 10 years with the discovery of newer drugs and targeted ...promotes ... See full document

... first-line treatment for advanced non-small cell lung cancer harboring ALK rearrange- ment is crizotinib ...a small molecule, oral tyrosine kinase inhibitor of ALK ...the ... See full document

... We conducted a comprehensive literature search of public databases, including PubMed, EMBASE, and the Cochrane library (up to April 30, 2017). Relevant search keywords included the followings: ... See full document

... by cancer cells to evade the host immune response are valuable targets for ...them. Cancer cells, however, can also change their microenvironment to an immunosuppressive state via cytokine expression (TGF- ... See full document

... second-line treatment of non-small cell lung cancer (NSCLC), and has since become a mainstay of NSCLC ...established role in the treatment of NSCLC and future ... See full document

... Abstract: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) were initially established as second- or third-line treatment of advanced non-small-cell lung ... See full document

... While treatment strategies for non-small cell lung cancer (NSCLC) has made substantial progress in the past two decades with the advent of molecular targeted agents and immune ... See full document

... the regions recognized by the paratopes. This feature makes these antibodies particularly useful, because they have the potential of not only interfering with ligand-facilitated activation of Notch, but also interfering ... See full document

... previous treatment assignments occurred through a fairly standardized process: (1) diagnose, (2) stage, and (3) use histology and staging information to ...a treatment option; and (3) if neither EGFR nor ... See full document

... RNAseq showing an increase in EMT markers such as vimentin, AXL, ZEB1, CDH5, and FN1, whereas epithelial markers such as E-cadherin, MIR200B, CLDN4, EPCAM, and CLDN7 were downregulated. Also, these clones showed ... See full document

... of treatment was ...plasma. Treatment with osimertinib was also associated with better ORR compared with chemotherapy (71% vs 31%, odds ratio: ...longer treatment duration with osimertinib, this was ... See full document

... subsequent cancer treatment difference (257 [68%] patients in the afatinib group and 153 [79%] patients in the placebo group) may be attributable to the lack of a significant difference in OS between the ... See full document

... characteristics of the target patient population for radio- therapy. Moreover, emerging immunotherapy methods have brought new hope for lung cancer treatment. A randomized, double-blind ... See full document

... erlotinib treatment arm in the Asian subpopulation (HR ...erlotinib treatment produced a significantly higher ORR compared with placebo ...maintenance treatment provides a treatment option in ... See full document